USPTO serial 88369066
PHASIFY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 15, 2020
- Examiner
- KUNKLEMAN, SARAH E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with PHASIFY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Plus Government fees of $1,950
Owner
Phase Scientific International Limited
Kwun Tong, Kowloon, HK
Other trademarks owned by Phase Scientific International Limited
Phase Scientific International Limited
Kwun Tong, Kowloon, HK
Other trademarks owned by Phase Scientific International Limited
Phase Scientific International Limited
Shatin, N.T., HK
Other trademarks owned by Phase Scientific International Limited
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Laura M. Konkel
Laura M. Konkel Michael Best & Friedrich LLP790 N Water Street, Suite 2500Milwaukee, WI 53202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; Biological preparations for use in industry and science; Chemical test kits for the expression, amplification, purification and analysis of biological samples for laboratory or research use; Chemicals for use in industry and science; Diagnostic preparations for scientific or research use; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Reagents for scientific and research use; Biochemicals for in vitro and in vivo scientific use; Biochemicals, namely, polynucleotides for in vitro and in vivo scientific and research purposes | ACTIVE | — |
| 005 | Chemical preparations for pharmaceutical or medical purposes, namely, for cancer, pregnancy; Chemical preparations for pharmaceutical or medical purposes, namely, for infectious diseases; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, infectious diseases; Diagnostic preparations for medical or veterinary purposes; Medical diagnostic reagents and assays for testing of body fluids; Veterinary diagnostic reagents | ACTIVE | — |
| 009 | Bio-chips for research or scientific purposes; Laboratory apparatus and instruments for extracting nucleic acid, DNA, RNA, exosome, other biomarkers; Medical laboratory research instruments for preparation, modification and manipulation of samples containing biopolymers, namely, nucleic acids, proteins, and biomarkers; Medical laboratory research instruments for the separation, isolation, purification, and analysis of biopolymers, namely, nucleic acids, proteins, and biomarkers; Scientific apparatus and instruments for measuring relative DNA, RNA and protein and parts and fittings therefor; Scientific apparatus and instruments, namely, fluid handling device used for disposable bioprocessing applications and parts and fittings therefor; Scientific instrumentation for measuring relative concentration of an analyte in a fluid not for medical use | ACTIVE | — |
| 010 | Diagnostic apparatus for the detection of cancer; Medical diagnostic instruments for the analysis of body fluids; Sample preparation device for medical diagnostic uses | ACTIVE | — |
| 042 | Chemical, biochemical, biological and bacteriological research and analysis; Consulting services for others in the field of design, planning, and implementation project management of scientific research, analysis, and testing in the field of chemistry, genetics, biology and biochemistry; DNA analysis services for scientific research purposes; Research and development and consultation related thereto in the field of chemistry, genetics, biology and biochemistry; Scientific and technological services, namely, research and design in the field of biology, biomedicine, and biotechnology, molecular diagnostics and molecular medicine; Custom design and development of chemical reagents and biochemical assays | ACTIVE | — |
| 044 | Medical diagnosis of human diseases, namely, genetic, infectious, neurological, cardiovascular, cancerous, inflammatory, reproductive and developmental diseases; Medical diagnosis of ovary cancer, liver cancer, stomach cancer, pancreas cancer, esophagus cancer, colorectum cancer, lung cancer, or breast cancer; Medical diagnostic testing, monitoring and reporting services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Phase Scientific International Limited
- Other trademarks owned by Phase Scientific International Limited
- Other trademarks owned by Phase Scientific International Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PHASIFY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 15, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 16, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 16, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 16, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 16, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 8, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 8, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 8, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 8, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 28, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 28, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 28, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 28, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 28, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 28, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 28, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 28, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 23, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 23, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 23, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 23, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 15, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 29, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 29, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 9, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 24, 2020 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Aug 10, 2020 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Aug 10, 2020 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Aug 5, 2020 | ERTI | TEAS RESPONSE TO PETITION INQUIRY LETTER | — |
| Aug 4, 2020 | PILM | PETITION INQUIRY LETTER ISSUED | — |
| Jul 27, 2020 | APET | ASSIGNED TO PETITION STAFF | — |
| Jul 20, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 2, 2020 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jun 2, 2020 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Mar 17, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 13, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 13, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 13, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 11, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 11, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 11, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 11, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 11, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 11, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 12, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 17, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 23, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 23, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 3, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 14, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 13, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 20, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 6, 2019 | NWAP | NEW APPLICATION ENTERED | — |